Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 24Fallopian Tube Neoplasms 13Neoplasms 11Breast Neoplasms 11Triple Negative Breast Neoplasms 5Carcinoma, Ovarian Epithelial 5Solid Tumors 4Sarcoma 4Neoplasm Metastasis 4Sarcoma, Ewing 3Lymphoma 3Carcinoma 3Sarcoma, Kaposi 2Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Multiple Myeloma 2Lymphoma, T-Cell 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Advanced Solid Tumors 2AIDS-related Kaposi sarcoma 2Urinary Bladder Neoplasms 1Unrecognized Condition 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1

Interventions

Doxorubicin 3pembrolizumab 2Radiotherapy 2ribociclib 1peposertib 1montanide ISA 51 1liposomal doxorubicin 1itacitinib 1futibatinib 1cixutumumab 1belinostat 1baricitinib 1avelumab 1Specimen Handling 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Ifosfamide 1INCB039110 1Histamine H2 Antagonists 1Fluorouracil 1Famotidine 1Erlotinib Hydrochloride 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Histiocytoma, Malignant Fibrous × liposomal doxorubicin × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡